VI национальные рекомендации по диагностике и лечению кислотозависимых и
ассоциированных с Helicobacter pylori заболеваний (VI московские соглашения) – тема …

Recent evidence of distinct ITP pathophysiology has opened new exploratory avenues for
disease management. We will discuss the utility of investigations into these mechanisms of …

Immune thrombocytopenia (ITP) is an autoimmune process resulting in increased
destruction and inadequate production of platelets that can result in bleeding, fatigue, and …

The management of patients with immune thrombocytopenia (ITP) is rapidly evolving. Over
the last 15 years, a number of novel treatments have improved practice, with many steroid …

Background: It is commonly accepted that antibody‐mediated removal of platelets
represents a major mechanism of platelet destruction in immune thrombocytopenic purpura …

Intravenous IgG (IVIg) contains polyclonal immunoglobulin G (IgG) from thousands of
donors. It is administered at a low dose at regular intervals as antibody replacement therapy …

The use of rituximab for the treatment of immune thrombocytopenia was greeted
enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main …

Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia. It is
characterized by the presence of antiphospholipid antibodies (APL) that are directed against …

Primary immune thrombocytopenia is an autoimmune disorder of unknown cause affecting
both children and adults. The low peripheral blood platelet count is caused by premature …

Purpose Autoimmune cytopenia is frequently a presenting manifestation of common variable
immune deficiency (CVID). Studies characterizing the CVID phenotype associated with …